In contrast, ibrutinib was ineffective against MCL cells lines with constitutive activation of the noncannonical NF-κB pathway caused by genetic lesions in the regulatory components TRAF2 and BIRC3. Here, NFKB1 is linked to mantle cell lymphoma.